New Weekly Treatment Approved for Myasthenia Gravis
Adults with generalized myasthenia gravis now have a once-weekly self-injected option, shown in trials to improve muscle strength versus placebo.
Updated on Nov. 16, 2026 in Asthma

The U.S. Food and Drug Administration has approved KLYGEFA (gefurulimab-gaks) for generalized myasthenia gravis, a chronic autoimmune disorder that causes muscle weakness. The approval was announced November 16, 2026, and gives adults living with the condition a new once-weekly treatment option.
Why it matters
Generalized myasthenia gravis disrupts communication between nerves and muscles, and a new approved therapy expands the options available to patients and their care teams. The approval marks a step forward in treatment goals for a condition that affects roughly 37 people per 100,000 in the United States.
The approval rests on Phase III PREVAIL trial data, which showed MG-ADL score improvement from baseline at week 26 compared with placebo, with a clinically meaningful change appearing as early as week one. The source does not detail the trial's sample size or the size of the effect, and how the drug performs in routine clinical practice remains to be seen.
The players
Alexion, AstraZeneca Rare Disease
The rare disease business of AstraZeneca that develops treatments for complement-mediated and other rare conditions, and the developer of KLYGEFA.
Muscular Dystrophy Association
A U.S. nonprofit that funds neuromuscular disease research and runs a care center network, and that announced the approval.
The details
KLYGEFA is a dual-binding nanobody C5 inhibitor, a class of drug that targets key pathways involved in the immune system's attack on the neuromuscular junction, the point where nerves meet muscle. It is given as a once-weekly subcutaneous injection using a self-administered autoinjector. Alexion, AstraZeneca Rare Disease is the developer and is positioning KLYGEFA as the first and only drug of its kind approved for generalized myasthenia gravis.
Timeline
November 16, 2026: FDA approval of KLYGEFA was announced.
December 8, 2026: Alexion, AstraZeneca Rare Disease will hold an Industry Update Webinar on KLYGEFA.
Health Landscape
Complement C5 inhibitors have become an established approach for generalized myasthenia gravis, and KLYGEFA joins that existing class of approved therapies. The approval adds a once-weekly self-administered option to the treatment landscape for a condition whose management has been expanding over recent years.
If you or someone you care for lives with generalized myasthenia gravis, a new once-weekly self-administered option may be worth raising with a neurologist as you review current treatment choices. Whether KLYGEFA is appropriate depends on individual factors, so it is a conversation to have with your physician.
The takeaway
A newly approved once-weekly treatment for generalized myasthenia gravis expands options for people with the condition. Anyone with muscle weakness that worsens with activity should discuss it with a neurologist, and ask about the treatments available to them.
What happens next
Alexion, AstraZeneca Rare Disease will host an Industry Update Webinar on KLYGEFA on December 8, 2026, where families and clinicians can learn more about the treatment.
Further reading
Explore more on Asthma to see how other chronic respiratory and immune conditions are managed.





